Melvyn T. Chow

St Andrews Place
East Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

CXCL10 chemokine regulates heterogeneity of the CD8+ T cell response and viral set point during chronic infection.

CXCL10 chemokine regulates heterogeneity of the CD8+ T cell response and viral set point during chronic infection.

Journal: Immunity

Published: July 27, 2020

Chemokines and the immune response to cancer.

Chemokines and the immune response to cancer.

Journal: Immunity

Published: April 14, 2020

Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.

Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.

Journal: Immunity

Published: May 08, 2018

Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis.

Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis.

Journal: Oncoimmunology

Published: December 15, 2014

Chemokines in cancer.

Chemokines in cancer.

Journal: Cancer immunology research

Published: December 07, 2014

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.

Journal: Nature medicine

Published: March 05, 2014

Type I NKT-cell-mediated TNF-α is a positive regulator of NLRP3 inflammasome priming.

Type I NKT-cell-mediated TNF-α is a positive regulator of NLRP3 inflammasome priming.

Journal: European journal of immunology

Published: November 24, 2013

The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions.

The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions.

Journal: Nature immunology

Published: September 13, 2013

Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.

Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: August 22, 2013

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 23, 2013

NLRP3 promotes inflammation-induced skin cancer but is dispensable for asbestos-induced mesothelioma.

NLRP3 promotes inflammation-induced skin cancer but is dispensable for asbestos-induced mesothelioma.

Journal: Immunology and cell biology

Published: September 27, 2012

NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases.

NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases.

Journal: Cancer research

Published: September 19, 2012

Showing 1-12 of 14

Last Updated: 09/26/2026